Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.

摘要: Background and Objectives Though necessary for improved outcomes, surgical resection is often limited in patients with locally advanced pancreatic cancers (LAPCs). We evaluated the efficacy of approach adopted by our institution using modified FOLFIRINOX chemotherapy followed radiation concurrent gemcitabine or capecitabine LAPCs, an effort to enhance resectability while improving toxicity profile compared similar treatment regimens. Methods We included 29 consecutive LAPC treated at above this review. rates resection, locol control, survival outcomes cohort. Results The median follow up series was 15.2 months. Approximately half were unresectable presentation. After neoadjuvant therapy, 41.3% all able undergo their tumors 83% achieved R0 resection. One-year local control entire cohort 85%; one-year progression-free overall 49.2% 65.5%, respectively. High metastatic disease seen regardless resectability. There minimal toxicities cohort. Conclusions Neoadjuvant therapy induction chemoradiation presents a well-tolerated, promising LAPC. highlight need optimize systemic targeted agents adenocarcinoma. J. Surg. Oncol. 2015 111:1028–1034. © Wiley Periodicals, Inc.